|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 42813 |
FusionGeneSummary for ZFP36L1_FGB |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ZFP36L1_FGB | Fusion gene ID: 42813 | Hgene | Tgene | Gene symbol | ZFP36L1 | FGB | Gene ID | 677 | 2244 |
| Gene name | ZFP36 ring finger protein like 1 | fibrinogen beta chain | |
| Synonyms | BRF1|Berg36|ERF-1|ERF1|RNF162B|TIS11B|cMG1 | HEL-S-78p | |
| Cytomap | 14q24.1 | 4q31.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | mRNA decay activator protein ZFP36L1EGF-response factor 1TPA-induced sequence 11bZFP36-like 1butyrate response factor 1early response factor Berg36zinc finger protein 36, C3H type-like 1zinc finger protein 36, C3H1 type-like 1zinc finger protein, | fibrinogen beta chainbeta-fibrinogenepididymis secretory sperm binding protein Li 78pfibrinogen, B beta polypeptide | |
| Modification date | 20180523 | 20180520 | |
| UniProtAcc | Q07352 | P02675 | |
| Ensembl transtripts involved in fusion gene | ENST00000555997, ENST00000439696, ENST00000336440, ENST00000408913, | ENST00000302068, ENST00000509493, ENST00000502545, | |
| Fusion gene scores | * DoF score | 3 X 3 X 1=9 | 3 X 4 X 2=24 |
| # samples | 3 | 5 | |
| ** MAII score | log2(3/9*10)=1.73696559416621 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(5/24*10)=1.05889368905357 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: ZFP36L1 [Title/Abstract] AND FGB [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ZFP36L1 | GO:0000165 | MAPK cascade | 18326031|20166898 |
| Hgene | ZFP36L1 | GO:0009611 | response to wounding | 27182009 |
| Hgene | ZFP36L1 | GO:0010468 | regulation of gene expression | 20166898 |
| Hgene | ZFP36L1 | GO:0014065 | phosphatidylinositol 3-kinase signaling | 15538381 |
| Hgene | ZFP36L1 | GO:0031440 | regulation of mRNA 3'-end processing | 21832157 |
| Hgene | ZFP36L1 | GO:0032869 | cellular response to insulin stimulus | 15538381 |
| Hgene | ZFP36L1 | GO:0043488 | regulation of mRNA stability | 15467755|15538381|15687258|18326031|19179481|20702587|24700863|25014217|26542173 |
| Hgene | ZFP36L1 | GO:0045647 | negative regulation of erythrocyte differentiation | 20702587 |
| Hgene | ZFP36L1 | GO:0045657 | positive regulation of monocyte differentiation | 26542173 |
| Hgene | ZFP36L1 | GO:0061158 | 3'-UTR-mediated mRNA destabilization | 15467755|15538381|15687258|18326031|19179481|24700863|26542173 |
| Hgene | ZFP36L1 | GO:0070371 | ERK1 and ERK2 cascade | 25106868 |
| Hgene | ZFP36L1 | GO:0071320 | cellular response to cAMP | 19179481 |
| Hgene | ZFP36L1 | GO:0071356 | cellular response to tumor necrosis factor | 20166898 |
| Hgene | ZFP36L1 | GO:0071364 | cellular response to epidermal growth factor stimulus | 20166898 |
| Hgene | ZFP36L1 | GO:0071375 | cellular response to peptide hormone stimulus | 15467755|19179481 |
| Hgene | ZFP36L1 | GO:0071385 | cellular response to glucocorticoid stimulus | 20166898 |
| Hgene | ZFP36L1 | GO:0071560 | cellular response to transforming growth factor beta stimulus | 20166898 |
| Tgene | FGB | GO:0007160 | cell-matrix adhesion | 10903502 |
| Tgene | FGB | GO:0031639 | plasminogen activation | 16846481 |
| Tgene | FGB | GO:0034116 | positive regulation of heterotypic cell-cell adhesion | 8100742 |
| Tgene | FGB | GO:0034622 | cellular protein-containing complex assembly | 8910396 |
| Tgene | FGB | GO:0042730 | fibrinolysis | 16846481 |
| Tgene | FGB | GO:0043152 | induction of bacterial agglutination | 24367264 |
| Tgene | FGB | GO:0045907 | positive regulation of vasoconstriction | 15739255 |
| Tgene | FGB | GO:0045921 | positive regulation of exocytosis | 19193866 |
| Tgene | FGB | GO:0050714 | positive regulation of protein secretion | 19193866 |
| Tgene | FGB | GO:0051258 | protein polymerization | 12706644 |
| Tgene | FGB | GO:0051592 | response to calcium ion | 6777381 |
| Tgene | FGB | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 10903502|19193866 |
| Tgene | FGB | GO:0070527 | platelet aggregation | 6281794 |
| Tgene | FGB | GO:0072378 | blood coagulation, fibrin clot formation | 16846481 |
| Tgene | FGB | GO:0090277 | positive regulation of peptide hormone secretion | 19193866 |
| Tgene | FGB | GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 10903502 |
| Tgene | FGB | GO:2000352 | negative regulation of endothelial cell apoptotic process | 10903502 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BG568132 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3UTR | ENST00000555997 | ENST00000302068 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-intron | ENST00000555997 | ENST00000509493 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-3UTR | ENST00000555997 | ENST00000502545 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-3UTR | ENST00000439696 | ENST00000302068 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-intron | ENST00000439696 | ENST00000509493 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-3UTR | ENST00000439696 | ENST00000502545 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-3UTR | ENST00000336440 | ENST00000302068 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-intron | ENST00000336440 | ENST00000509493 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-3UTR | ENST00000336440 | ENST00000502545 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-3UTR | ENST00000408913 | ENST00000302068 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-intron | ENST00000408913 | ENST00000509493 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
| intron-3UTR | ENST00000408913 | ENST00000502545 | ZFP36L1 | chr14 | 69255154 | + | FGB | chr4 | 155491882 | + |
Top |
FusionProtFeatures for ZFP36L1_FGB |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ZFP36L1 | FGB |
| Zinc-finger RNA-binding protein that destabilizesseveral cytoplasmic AU-rich element (ARE)-containing mRNAtranscripts by promoting their poly(A) tail removal ordeadenylation, and hence provide a mechanism for attenuatingprotein synthesis (PubMed:12198173, PubMed:15538381,PubMed:15467755, PubMed:17030608, PubMed:19179481,PubMed:20702587, PubMed:24700863, PubMed:25106868,PubMed:25014217, PubMed:26542173). Acts as a 3'-untranslatedregion (UTR) ARE mRNA-binding adapter protein to communicatesignaling events to the mRNA decay machinery (PubMed:15687258).Functions by recruiting the CCR4-NOT deadenylase complex andcomponents of the cytoplasmic RNA decay machinery to the boundARE-containing mRNAs, and hence promotes ARE-mediated mRNAdeadenylation and decay processes (PubMed:15687258,PubMed:18326031, PubMed:25106868). Induces also the degradation ofARE-containing mRNAs even in absence of poly(A) tail (Bysimilarity). Binds to 3'-UTR ARE of numerous mRNAs(PubMed:12198173, PubMed:15538381, PubMed:15467755,PubMed:17030608, PubMed:19179481, PubMed:20702587,PubMed:24700863, PubMed:25106868, PubMed:25014217,PubMed:26542173). Positively regulates early adipogenesis bypromoting ARE-mediated mRNA decay of immediate early genes (IEGs)(By similarity). Promotes ARE-mediated mRNA decay ofmineralocorticoid receptor NR3C2 mRNA in response to hypertonicstress (PubMed:24700863). Negatively regulateshematopoietic/erythroid cell differentiation by promoting ARE-mediated mRNA decay of the transcription factor STAT5B mRNA(PubMed:20702587). Positively regulates monocyte/macrophage celldifferentiation by promoting ARE-mediated mRNA decay of thecyclin-dependent kinase CDK6 mRNA (PubMed:26542173). Promotesdegradation of ARE-containing pluripotency-associated mRNAs inembryonic stem cells (ESCs), such as NANOG, through a fibroblastgrowth factor (FGF)-induced MAPK-dependent signaling pathway, andhence attenuates ESC self-renewal and positively regulatesmesendoderm differentiation (By similarity). May play a role inmediating pro-apoptotic effects in malignant B-cells by promotingARE-mediated mRNA decay of BCL2 mRNA (PubMed:25014217). Inassociation with ZFP36L2 maintains quiescence on developing Blymphocytes by promoting ARE-mediated decay of several mRNAsencoding cell cycle regulators that help B cells progress throughthe cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination and functional immune cell formation(By similarity). Together with ZFP36L2 is also necessary forthymocyte development and prevention of T-cell acute lymphoblasticleukemia (T-ALL) transformation by promoting ARE-mediated mRNAdecay of the oncogenic transcription factor NOTCH1 mRNA (Bysimilarity). Participates in the delivery of target ARE-mRNAs toprocessing bodies (PBs) (PubMed:17369404). In addition to itscytosolic mRNA-decay function, plays a role in the regulation ofnuclear mRNA 3'-end processing; modulates mRNA 3'-end maturationefficiency of the DLL4 mRNA through binding with an ARE embeddedin a weak noncanonical polyadenylation (poly(A)) signal inendothelial cells (PubMed:21832157). Also involved in theregulation of stress granule (SG) and P-body (PB) formation andfusion (PubMed:15967811). Plays a role in vasculogenesis andendocardial development (By similarity). Plays a role in theregulation of keratinocyte proliferation, differentiation andapoptosis (PubMed:27182009). Plays a role in myoblast celldifferentiation (By similarity). {ECO:0000250|UniProtKB:P17431,ECO:0000250|UniProtKB:P23950, ECO:0000269|PubMed:12198173,ECO:0000269|PubMed:15467755, ECO:0000269|PubMed:15538381,ECO:0000269|PubMed:15687258, ECO:0000269|PubMed:15967811,ECO:0000269|PubMed:17030608, ECO:0000269|PubMed:17369404,ECO:0000269|PubMed:18326031, ECO:0000269|PubMed:19179481,ECO:0000269|PubMed:20702587, ECO:0000269|PubMed:21832157,ECO:0000269|PubMed:24700863, ECO:0000269|PubMed:25014217,ECO:0000269|PubMed:25106868, ECO:0000269|PubMed:26542173,ECO:0000269|PubMed:27182009}. | Cleaved by the protease thrombin to yield monomerswhich, together with fibrinogen alpha (FGA) and fibrinogen gamma(FGG), polymerize to form an insoluble fibrin matrix. Fibrin has amajor function in hemostasis as one of the primary components ofblood clots. In addition, functions during the early stages ofwound repair to stabilize the lesion and guide cell migrationduring re-epithelialization. Was originally thought to beessential for platelet aggregation, based on in vitro studiesusing anticoagulated blood. However subsequent studies have shownthat it is not absolutely required for thrombus formation in vivo.Enhances expression of SELP in activated platelets. Maternalfibrinogen is essential for successful pregnancy. Fibrindeposition is also associated with infection, where it protectsagainst IFNG-mediated hemorrhage. May also facilitate theantibacterial immune response via both innate and T-cell mediatedpathways. {ECO:0000250|UniProtKB:E9PV24}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ZFP36L1_FGB |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ZFP36L1_FGB |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ZFP36L1_FGB |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | FGB | P02675 | DB00364 | Sucralfate | Fibrinogen beta chain | small molecule | approved |
| Tgene | FGB | P02675 | DB13151 | Anti-inhibitor coagulant complex | Fibrinogen beta chain | biotech | approved|investigational |
Top |
RelatedDiseases for ZFP36L1_FGB |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | FGB | C2584774 | Congenital hypofibrinogenemia | 4 | ORPHANET;UNIPROT |
| Tgene | FGB | C0029456 | Osteoporosis | 1 | CTD_human |
| Tgene | FGB | C0030567 | Parkinson Disease | 1 | CTD_human |
| Tgene | FGB | C0272350 | Dysfibrinogenemia, Congenital | 1 | ORPHANET;UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|